13F Holdings
中文EN

ABBV AbbVie Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1551152 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.6%
TTM net income YoY-1.2%
TTM EPS YoY-1.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR-29.1%

Margins

Gross margin70.2%
Operating margin24.6%
Net margin6.9%
FCF margin29.1%
EBITDA margin25.9%

Returns

ROE15,367.3%
ROA3.1%
ROIC (approx.)17.4%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets102.4%
Debt / equity—
Current ratio0.67x
Interest coverage5.21x

Cash quality & payout

Operating cash flow / net income4.50x
Accruals ratio-11.0%
Payout ratio275.8%
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$61.16B$56.33B$54.32B$58.05B$56.20B
Cost of revenue$18.20B$16.90B$20.41B$17.41B$17.45B
Gross profit$42.96B$39.43B$33.90B$40.64B$38.75B
R&D expense$9.10B$12.79B$7.67B$6.51B$6.92B
SG&A expense$14.01B$14.75B$12.87B$15.26B$12.35B
Operating income$15.07B$9.14B$12.76B$18.12B$17.92B
Interest expense$2.89B$2.81B$2.22B$2.23B$2.42B
Pretax income$6.60B$3.72B$6.25B$13.48B$12.99B
Income tax$2.36B-$570.00M$1.38B$1.63B$1.44B
Net income$4.23B$4.28B$4.86B$11.84B$11.54B
EBITDA$15.84B$9.90B$13.51B$18.89B$18.73B
EPS (basic)2.372.402.736.656.48
EPS (diluted)2.362.392.726.636.45
Dividends declared per share6.656.295.995.715.31
Weighted avg. shares (diluted)1.77B1.77B1.77B1.78B1.78B
Balance sheet
Cash & equivalents$5.23B$5.52B$12.81B$9.20B$9.75B
Short-term investments$28.00M$31.00M$2.00M$28.00M$84.00M
Receivables$12.59B$10.92B$11.15B$11.25B$9.98B
Inventory$4.95B$4.18B$4.10B$3.58B$3.13B
Current assets$29.06B$25.58B$33.00B$28.46B$27.93B
PP&E, net$5.63B$5.13B$4.99B$4.93B$5.11B
Goodwill$35.64B$34.96B$32.29B$32.16B$32.38B
Intangibles$52.64B$60.07B$55.61B$67.44B$75.95B
Total assets$133.96B$135.16B$134.71B$138.81B$146.53B
Current liabilities$43.29B$38.75B$37.84B$29.54B$35.19B
Short-term debt$2.50B$0$7.19B$1.00M$14.00M
Long-term debt$58.94B$60.34B$52.19B$59.13B$64.19B
Total debt$61.44B$60.34B$59.38B$59.14B$64.20B
Total liabilities$137.19B$131.80B$124.31B$121.52B$131.09B
Shareholders' equity-$3.27B$3.33B$10.36B$17.25B$15.41B
Net debt$56.21B$54.82B$46.57B$49.94B$54.46B
Cash flow statement
Operating cash flow$19.03B$18.81B$22.84B$24.94B$22.78B
Capital expenditure$1.21B$974.00M$777.00M$695.00M$787.00M
Free cash flow$17.82B$17.83B$22.06B$24.25B$21.99B
Investing cash flow-$6.64B-$20.82B-$2.01B-$623.00M-$2.34B
Financing cash flow-$12.72B-$5.21B-$17.22B-$24.80B-$19.04B
Depreciation & amortization$762.00M$764.00M$752.00M$778.00M$803.00M
Stock-based compensation$955.00M$911.00M$747.00M$671.00M$692.00M
Dividends paid$11.66B$11.03B$10.54B$10.04B$9.26B
Share buybacks$980.00M$1.71B$1.97B$1.49B$934.00M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.